These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27194646)

  • 1. Sixty seconds on . . . psilocybin.
    Hawkes N
    BMJ; 2016 May; 353():i2775. PubMed ID: 27194646
    [No Abstract]   [Full Text] [Related]  

  • 2. Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future.
    Nutt D
    J Psychopharmacol; 2016 Dec; 30(12):1163-1164. PubMed ID: 27909163
    [No Abstract]   [Full Text] [Related]  

  • 3. Return of the psychedelics: Psilocybin for treatment resistant depression.
    Patra S
    Asian J Psychiatr; 2016 Dec; 24():51-52. PubMed ID: 27931907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia.
    Strauss N
    Med J Aust; 2017 Jun; 206(11):468-469. PubMed ID: 28918722
    [No Abstract]   [Full Text] [Related]  

  • 5. Psilocybin-induced stimulus control in the rat.
    Winter JC; Rice KC; Amorosi DJ; Rabin RA
    Pharmacol Biochem Behav; 2007 Oct; 87(4):472-80. PubMed ID: 17688928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of psilocybin on time perception and temporal control of behaviour in humans.
    Wittmann M; Carter O; Hasler F; Cahn BR; Grimberg U; Spring P; Hell D; Flohr H; Vollenweider FX
    J Psychopharmacol; 2007 Jan; 21(1):50-64. PubMed ID: 16714323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psilocybin-assisted therapy for depression: How do we advance the field?
    Meikle SE; Liknaitzky P; Rossell SL; Ross M; Strauss N; Thomas N; Murray G; Williams M; Castle DJ
    Aust N Z J Psychiatry; 2020 Mar; 54(3):225-231. PubMed ID: 31752499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psilocybin: a pharmacological profile.
    Aboul-Enein HY
    Am J Pharm Sci Support Public Health; 1974; 146(3):91-5. PubMed ID: 4853936
    [No Abstract]   [Full Text] [Related]  

  • 10. Reviving the study of hallucinogens.
    Harv Ment Health Lett; 2006 Oct; 23(4):5. PubMed ID: 17183740
    [No Abstract]   [Full Text] [Related]  

  • 11. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The psychedelic escape from depression.
    Eisenstein M
    Nature; 2022 Sep; 609(7929):S87-S89. PubMed ID: 36171370
    [No Abstract]   [Full Text] [Related]  

  • 13. Increased activation of indirect semantic associations under psilocybin.
    Spitzer M; Thimm M; Hermle L; Holzmann P; Kovar KA; Heimann H; Gouzoulis-Mayfrank E; Kischka U; Schneider F
    Biol Psychiatry; 1996 Jun; 39(12):1055-7. PubMed ID: 8780843
    [No Abstract]   [Full Text] [Related]  

  • 14. II. The effects of some hallucinogens on aggressiveness of mice and rats.
    Kostowski W; Rewerski W; Piechocki T
    Pharmacology; 1972; 7(4):259-63. PubMed ID: 4672886
    [No Abstract]   [Full Text] [Related]  

  • 15. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
    Barrett FS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of the cortical tracings of "sleep" induced in the waking cat by 3 hallucinogens].
    Rougeul A; Verdeaux J; Buser P
    Rev Neurol (Paris); 1966 Jul; 115(1):181-4. PubMed ID: 5956458
    [No Abstract]   [Full Text] [Related]  

  • 17. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.
    Lyons T; Carhart-Harris RL
    J Psychopharmacol; 2018 Jul; 32(7):811-819. PubMed ID: 29338538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is psilocybin an effective antidepressant and what is its Mechanism of action?
    Mann JJ
    Cell Rep Med; 2023 Jan; 4(1):100906. PubMed ID: 36652915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations.
    Kometer M; Cahn BR; Andel D; Carter OL; Vollenweider FX
    Biol Psychiatry; 2011 Mar; 69(5):399-406. PubMed ID: 21126732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psilocybin: Good Trip or Bad Trip.
    Sellers EM
    Clin Pharmacol Ther; 2017 Oct; 102(4):580-584. PubMed ID: 28548221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.